Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone973-822-7000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$6.26 billion
Profitability
Miscellaneous
Employees10,000
Next Earnings Date5/7/2020 (Estimated)
OptionableOptionable
Zoetis (NYSE:ZTS) Frequently Asked Questions
What is Zoetis' stock symbol?
Zoetis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZTS."
How often does Zoetis pay dividends? What is the dividend yield for Zoetis?
Zoetis announced a quarterly dividend on Tuesday, February 11th. Shareholders of record on Friday, April 17th will be given a dividend of $0.20 per share on Monday, June 1st. This represents a $0.80 dividend on an annualized basis and a yield of 0.56%. The ex-dividend date is Thursday, April 16th. View Zoetis' Dividend History.
How will Zoetis' stock buyback program work?
Zoetis announced that its board has approved a stock repurchase plan on Wednesday, December 12th 2018, which authorizes the company to buyback $2,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to purchase up to 4.7% of its stock through open market purchases. Stock buyback plans are usually an indication that the company's management believes its shares are undervalued.
How were Zoetis' earnings last quarter?
Zoetis Inc (NYSE:ZTS) released its quarterly earnings results on Thursday, February, 13th. The company reported $0.92 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.88 by $0.04. The company had revenue of $1.67 billion for the quarter, compared to analyst estimates of $1.64 billion. Zoetis had a return on equity of 69.41% and a net margin of 23.96%. The business's revenue for the quarter was up 7.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.79 EPS. View Zoetis' Earnings History.
When is Zoetis' next earnings date?
What guidance has Zoetis issued on next quarter's earnings?
Zoetis issued an update on its FY20 earnings guidance on Thursday, February, 13th. The company provided EPS guidance of $3.90-4.00 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.01. The company issued revenue guidance of $6.65-6.80 billion, compared to the consensus revenue estimate of $6.69 billion.
What price target have analysts set for ZTS?
16 equities research analysts have issued 12 month price targets for Zoetis' stock. Their forecasts range from $105.00 to $160.00. On average, they expect Zoetis' stock price to reach $135.07 in the next twelve months. This suggests that the stock has a possible downside of 6.0%. View Analyst Price Targets for Zoetis.
What is the consensus analysts' recommendation for Zoetis?
16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last year. There are currently 7 hold ratings, 7 buy ratings and 2 strong buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zoetis.
Has Zoetis been receiving favorable news coverage?
News stories about ZTS stock have been trending positive on Wednesday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Zoetis earned a coverage optimism score of 2.8 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days. View News Stories for Zoetis.
Are investors shorting Zoetis?
Zoetis saw a decrease in short interest during the month of January. As of January 31st, there was short interest totalling 5,190,000 shares, a decrease of 12.6% from the January 15th total of 5,940,000 shares. Based on an average trading volume of 2,140,000 shares, the days-to-cover ratio is currently 2.4 days. Approximately 1.1% of the shares of the company are short sold. View Zoetis' Current Options Chain.
Who are some of Zoetis' key competitors?
Some companies that are related to Zoetis include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Allergan (AGN), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), The Medicines (MDCO), Horizon Therapeutics (HZNP), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX) and Corcept Therapeutics (CORT).
What other stocks do shareholders of Zoetis own?
Who are Zoetis' key executives?
Zoetis' management team includes the folowing people:
- Mr. Juan Ramón Alaix, CEO & Director (Age 68)
- Mr. Glenn C. David, Exec. VP & CFO (Age 47)
- Dr. Catherine A. Knupp, Exec. VP and Pres of R&D (Age 58)
- Mr. Clinton A. Lewis Jr., EVP and Grp Pres of Intl. Ops., Comm. Devp., Glbl Genetics, Aquatic Health & Human Medical Digs (Age 52)
- Ms. Kristin C. Peck, Exec. VP and Group Pres of U.S. Operations, Bus. Devel. & Strategy (Age 48)
Who are Zoetis' major shareholders?
Zoetis' stock is owned by many different of retail and institutional investors. Top institutional investors include State Street Corp (4.17%), Alliancebernstein L.P. (2.94%), FMR LLC (2.45%), Polen Capital Management LLC (2.27%), Capital World Investors (2.02%) and Massachusetts Financial Services Co. MA (1.67%). Company insiders that own Zoetis stock include Andrew Fenton, Catherine A Knupp, Clinton A Jr Lewis, Glenn David, Heidi C Chen, Juan Ramon Alaix, Khosla Sanjay, Kristin C Peck, Roman Trawicki, Roxanne Lagano and Willie M Reed. View Institutional Ownership Trends for Zoetis.
Which institutional investors are selling Zoetis stock?
ZTS stock was sold by a variety of institutional investors in the last quarter, including Sonora Investment Management LLC, Capital World Investors, Janus Henderson Group PLC, FMR LLC, Cantillon Capital Management LLC, Artemis Investment Management LLP, Renaissance Technologies LLC and Eaton Vance Management. Company insiders that have sold Zoetis company stock in the last year include Andrew Fenton, Catherine A Knupp, Clinton A Jr Lewis, Glenn David, Heidi C Chen, Juan Ramon Alaix, Kristin C Peck, Roman Trawicki, Roxanne Lagano and Willie M Reed. View Insider Buying and Selling for Zoetis.
Which institutional investors are buying Zoetis stock?
ZTS stock was purchased by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Sands Capital Management LLC, Goldman Sachs Group Inc., Milestone Resources Group Ltd, Marshall Wace LLP, Credit Suisse AG, UBS Group AG and Massachusetts Financial Services Co. MA. View Insider Buying and Selling for Zoetis.
How do I buy shares of Zoetis?
Shares of ZTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Zoetis' stock price today?
One share of ZTS stock can currently be purchased for approximately $143.65.
How big of a company is Zoetis?
Zoetis has a market capitalization of $68.42 billion and generates $6.26 billion in revenue each year. The company earns $1.50 billion in net income (profit) each year or $3.64 on an earnings per share basis. Zoetis employs 10,000 workers across the globe.View Additional Information About Zoetis.
What is Zoetis' official website?
How can I contact Zoetis?
Zoetis' mailing address is 10 Sylvan Way, Parsippany NJ, 07054. The company can be reached via phone at 973-822-7000 or via email at [email protected]
MarketBeat Community Rating for Zoetis (NYSE ZTS)
MarketBeat's community ratings are surveys of what our community members think about Zoetis and other stocks. Vote "Outperform" if you believe ZTS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZTS will underperform the S&P 500 over the long term. You may vote once every thirty days.
